RxDoctor Payments Data

Erika Andres

Family · Cincinnati, OHNPI 1144701574

Payments from drug & device makers

$6,520in general payments, 2019–2025

Across 416 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$985
  • AstraZeneca$527
  • Lilly USA, LLC$436
  • Pfizer$371
  • Abbott$349
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$6,520100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,520 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$41,614
Medicare patients
234
Services billed
599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$37,931
TrulicityDulaglutide27$35,716
OzempicSemaglutide20$33,839
JardianceEmpagliflozin31$32,957
XareltoRivaroxaban23$25,021
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$13,084
Varenicline Tartrate16$7,166
Spiriva HandihalerTiotropium Bromide11$5,541
Breo ElliptaFluticasone/Vilanterol12$4,809
Humalog Kwikpen U-100Insulin Lispro17$3,676
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$3,648
Atorvastatin Calcium211$1,815
Diltiazem 24hr Er (Cd)Diltiazem Hcl21$1,650
Albuterol Sulfate HfaAlbuterol Sulfate37$1,374
SynthroidLevothyroxine Sodium18$1,307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$371$37,93139 claims
Lilly USA, LLCTrulicity$436$35,71627 claims
Novo NordiskOzempic$985$33,83920 claims
Boehringer IngelheimJardiance$221$32,95731 claims
Johnson & JohnsonXarelto$64$25,02123 claims
GSKTrelegy Ellipta, Breo Ellipta$259$17,89327 claims
AbbVieSynthroid$1,250$1,30718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →